Global HMO Industry Expected to Hit $556


Dublin, Nov. 03, 2022 (GLOBE NEWSWIRE) — The “HMO Market by Type (2′ Fl, 3′ Fl, 3′ Sl, 6′ Sl), Application (Infant Formula, Functional Food & Beverage, Dietary Supplement), Concentration (Acid, Neutral) and Region (North America , Europe , APAC, South America, RoW) – Global Forecast to 2027″ report has been added to from ResearchAndMarkets.com offer.

The global HMO Market market is esteemed at USD 199 Million in 2022. It is expected to reach USD 556 Million by 2027, registering a CAGR of 22.7% during the forecast period.

The Asia-Pacific region is expected to grow by 23.2% over the forecast period

The Asia-Pacific region accounts for USD 92.6 million of the global HMO market size. The region is expected to grow at the highest CAGR over the forecast period, maintaining its dominance as the leading market for HMOs. Asia-Pacific is the most densely populated region made up of countries like China, India, Japan, Australia, and New Zealand and others. It is also one of the key markets for HMOs.

China is a dominant market in the region, as it is one of the largest infant formula consumers in the world. Therefore, any fluctuation in the market in China is expected to significantly affect the global infant formula market, which in turn will affect the HMO market. China is expected to be the largest market for human milk oligosaccharides (HMOs) in 2022.

The country has seen a high adoption of infant formula made with premium ingredients, including HMOs, mainly due to increasing income level, modernization and middle class population. The Chinese government has started to relax its stance on the one-child policy and allows couples to have two children. This is expected to increase the number of newborns, which in turn will drive the demand for HMOs.

The 2′ FL type is rapidly gaining popularity in the HMO market across the world

HMOs are known to have Bifidus, a species of beneficial bacteria also known as Bifidobacterium. 2’FL grows selectively in intestinal Bifidobacterium due to three different categories of bifidobacteria, such as B. dentium, Bifidobacterium bifidum and B. infantis. Due to their numerous health benefits and wide range of applications, 2’FL-based HMOs have become popular in recent years.

Various government agencies grant approval for their industrial and commercial use. For instance; in July 2021, according to the Taiwan Food and Drug Administration, Taiwan has authorized the use of human milk oligosaccharides (HMO) 2’FL in infant formula, milk formula for children under seven years old, formula food for children under seven and growth-up formula. The authorized use of this formula is 1.2 g/litre. The 2’FL segment is estimated to dominate the market in 2022, owing to continuous rigorous research in the development of 2’FL-based HMOs by key players.

Extensive R&D activities of infant formula manufacturers

Infant formulas are made from industrially modified products. It is intended for use as a breast milk substitute and is formulated by manufacturers to mimic the nutritional composition of breast milk for the overall growth and development of infants. According to an article published by the National Library of Medicine in June 2019, from the age of 6 months, an infant’s energy and nutrient needs begin to exceed those provided by breast milk.

Main topics covered:

1. Introduction

2. Research methodology

3 Executive summary

4 premium previews
4.1 Attractive Opportunities in Hmo Market
4.2 Human Milk Oligosaccharides Market, by Region
4.3 Human Milk Oligosaccharides Market, by Type
4.4 Human Milk Oligosaccharides Market, By Concentration
4.5 Human Milk Oligosaccharides Market, by Application
4.6 Asia Pacific: Hmo Market, by Type and Key Country

5. Market Overview
5.1 Presentation
5.2 Macroeconomic indicators
5.2.1 Digitization of the retail sector
5.2.2 Increase in the number of dual-income households
5.2.3 Rapid urbanization in all regions
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increase in child population
5.3.1.2 Growing Health Awareness Leading to Increased Consumption of Dietary Supplements
5.3.1.3 Extensive R&D Initiatives of Companies Operating in Infant Formula Market
5.3.2 Constraints
5.3.2.1 Higher Production Costs Associated with the Development of Hmo-Compound Supplements and Dietary Products
5.3.2.2 Strict trade regulations and policies in the infant formula and dietary supplement industries
5.3.3 Opportunities
5.3.3.1 Emergence of alternative animal milk oligosaccharides
5.3.3.2 Adoption of advanced technologies in the functional food industry
5.3.4 Challenges
5.3.4.1 Complex industrial process to extract oligosaccharides from milk
5.3.4.2 Lack of consumer awareness of the benefits associated with products formulated with Hmo
5.4 Key conferences and events
5.5 Key Stakeholders and Purchase Criteria

6. Industry trends
6.1 Overview
6.2 Regulatory framework
6.3 North America
6.3.1 Canada
6.3.2 United States
6.3.3 Mexico
6.4 European Union (eu)
6.5 Asia-Pacific
6.5.1 Japan
6.5.2 China
6.5.3 India
6.5.4 Australia and New Zealand
6.6 South America
6.6.1 Brazil
6.6.2 Argentina
6.7 Rest of the world (line)
6.7.1 Middle East
6.8 Regulatory Bodies
6.9 Patent analysis
6.10 Value chain analysis
6.11 Impact of COVID-19 on the Human Milk Oligosaccharides Market
6.12 Trend/Disruption Affecting Buyers in Human Milk Oligosaccharides Market
6.13 Market ecosystem
6.14 Technological analysis
6.14.1 High performance anion exchange chromatography for human milk oligosaccharide analysis
6.14.2 Capillary electrophoresis for human milk oligosaccharide analysis
6.15 Porter’s Five Forces Analysis
6.15.1 Intensity of Competitive Rivalry
6.15.2 Bargaining power of suppliers
6.15.3 Bargaining power of buyers
6.15.4 Threat of Substitutes
6.15.5 Threat of new entrants
6.16 Analysis of case studies
6.16.1 Use case 1: Layer Origin introduces easy to use and effective prebiotic pills and powder for Hmo for adults
6.17 Price Analysis
6.17.1 Presentation
6.17.2 Price Analysis: Human Milk Oligosaccharides Market, by Type, 2017- 2021 (USD per/Kg)
6.17.3 Price Analysis: Human Milk Oligosaccharides Market, by Region, 2017- 2021 (USD per/Kg)

7. Human Milk Oligosaccharides (HMOs) Market, By Type
7.1 Presentation
7.1.1 Human Milk Oligosaccharides Market: Impact Analysis of COVID-19 – By Type
7.2 2’Fl
7.2.1 Authorization of Hmos by government agencies for consumption
7.3 3’Fl
7.3.1 3’Fl Prebiotic Quality Expected to Propel Human Milk Oligosaccharides Market Growth in Coming Years
7.4 3’sl
7.4.1 Importance of 3’sl in early childhood language development
7.5 6’sl
7.5.1 Wide Use of HMOs in Industries

8. Breast Milk Oligosaccharides Market, By Application
8.1 Presentation
8.1.1 Extensive R&D Activities of Infant Formula Manufacturers
8.2 Functional foods and beverages
8.2.1 Role of Fast Lifestyle and Rising Adoption of Ready-to-Eat Food Products in the Growth of Functional Foods and Beverages
8.3 Food Supplements
8.3.1 Growing Health Awareness and Growing Demand for Nutrient-Dense Food Products
8.4 Other applications
8.4.1 Wide Use of HMOs in Industries

9. Breast Milk Oligosaccharides Market, By Concentration
9.1 Presentation
9.2 Neutral
9.2.1 Growing Consumer Concerns About Gut Health and Immunity in Infants
9.3 Acid
9.3.1 Imitation of breast milk in premium infant formula

10. Human Milk Oligosaccharides (HMOs) Market, By Region

11. Competitive landscape
11.1 Overview
11.2 Market Share Analysis, 2021
11.3 Strategies of Key Players
11.4 Historical Revenue Analysis of Key Players
11.5 Specific business response to COVID-19
11.5.1 DSMs
11.5.2 BasfSe
11.5.3 Smith
11.5.4 Chr Hansen Holding A/S
11.6 Company Assessment Quadrant (Key Players)
11.6.1 Stars
11.6.2 Emerging Leaders
11.6.3 Ubiquitous Players
11.6.4 Participants
11.7 Product footprint
11.8 Startup/SME Assessment Quadrant (Other Players)
11.8.1 Progressive companies
11.8.2 Starting Blocks
11.8.3 Sensitive businesses
11.8.4 Dynamic companies
11.9 Competitive Scenario
11.9.1 New Product Launches
11.9.2 Offers

12. Company Profiles
12.1 Key Players
12.1.1 MDS
12.1.2 BASF SE.
12.1.3 Chr Hansenholding A/S
12.1.4 Smith
12.1.5 Nestle
12.1.6 Biosynth Carbosynth
12.1.7 Inbiosis Lv.
12.1.8 Gnubiotics Sciences SA
12.1.9 Abbott Laboratories
12.1.10 Royal Frieslandcampina SA
12.1.11 Elicityl SA
12.1.12 Dextra Laboratories Ltd.
12.2 Start-ups/SMEs/Other Players
12.2.1 Zuchem Inc.
12.2.2 Advanced Protein Technologies Corp.
12.2.3 Conagen Inc.
12.2.4 Kyowa Hakko Bio Co. Ltd.
12.2.5 Medolac Laboratories
12.3 End User Business Profiles
12.3.1 H&H Group
12.3.2 Original layer nutrition
12.3.3 Standard Process Inc.
12.3.4 Reckitt Benckiser Group
12.3.5 Amazon

13. Adjacent and Related Markets

14. Appendix

For more information on this report, visit https://www.researchandmarkets.com/r/q7w36f


        
Previous Meta adds new tools to help content creators make money on Instagram
Next Eric Schmitt pays $75,000 for ad during Chiefs game to close Missouri Senate race Missouri Independent